Tenaya Therapeutics, Inc.

# Signal Note: Casdin Capital Initiates TNYA Position Casdin's entry into Tenaya signals conviction in the company's cardiac regenerative medicine platform, particularly TNYA-001 for heart failure—a large market (~6.5M US patients) with limited regenerative options. The timing aligns with Tenaya's anticipated clinical readouts from its Phase 1b/2a trial, expected in H2 2024-2025, which could validate safety and early efficacy of this allogeneic cardiomyocyte therapy.